Emre et al
1
report that moderate-to-severe nonalcoholic fatty liver disease (NAFLD) is independently
related with impaired myocardial perfusion and with poorer in-hospital prognosis after
primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction.
In-hospital major adverse cardiac events (MACE) occurred in 31% versus 8% (p <0.0001)
of patients with moderate-to-severe and mild NAFLD, respectively.
- Emre A.
- Terzi S.
- Celiker E.
- Sahin S.
- Yazici S.
- Erdem A.
- Ceylan U.S.
- Asik M.
- Yesilcimen K.
Impact of nonalcoholic fatty liver disease on myocardial perfusion in nondiabetic
patients undergoing primary percutaneous coronary intervention for ST-segment elevation
myocardial infarction.
Am J Cardiol. 2015; 116: 1810-1814
1
NAFLD severity was evaluated with a semiquantitative score and was characterized
as mild if the score was <3 or moderate to severe if the score was ≥3. Postprocedural
myocardial perfusion was evaluated with myocardial blush grade and ST-segment resolution.
- Emre A.
- Terzi S.
- Celiker E.
- Sahin S.
- Yazici S.
- Erdem A.
- Ceylan U.S.
- Asik M.
- Yesilcimen K.
Impact of nonalcoholic fatty liver disease on myocardial perfusion in nondiabetic
patients undergoing primary percutaneous coronary intervention for ST-segment elevation
myocardial infarction.
Am J Cardiol. 2015; 116: 1810-1814
1
In this context, we previously reported that NAFLD is related with excess risk of cardiac
events
- Emre A.
- Terzi S.
- Celiker E.
- Sahin S.
- Yazici S.
- Erdem A.
- Ceylan U.S.
- Asik M.
- Yesilcimen K.
Impact of nonalcoholic fatty liver disease on myocardial perfusion in nondiabetic
patients undergoing primary percutaneous coronary intervention for ST-segment elevation
myocardial infarction.
Am J Cardiol. 2015; 116: 1810-1814
2
,
- Athyros V.G.
- Tziomalos K.
- Gossios T.D.
- Griva T.
- Anagnostis P.
- Kargiotis K.
- Pagourelias E.D.
- Theocharidou E.
- Karagiannis A.
- Mikhailidis D.P.
GREACE Study Collaborative Group
Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis.
Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis.
Lancet. 2010; 376: 1916-1922
3
both in patients with or without established cardiovascular disease.
- Athyros V.G.
- Giouleme O.
- Ganotakis E.S.
- Elisaf M.
- Tziomalos K.
- Vassiliadis T.
- Liberopoulos E.N.
- Elisaf M.
- Tziomalos K.
- Vassiliadis T.
- Liberopoulos E.N.
for the Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes
(ATTEMPT) Collaborative Group
Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT Study.
Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT Study.
Arch Med Sci. 2011; 7: 796-805
2
,
- Athyros V.G.
- Tziomalos K.
- Gossios T.D.
- Griva T.
- Anagnostis P.
- Kargiotis K.
- Pagourelias E.D.
- Theocharidou E.
- Karagiannis A.
- Mikhailidis D.P.
GREACE Study Collaborative Group
Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis.
Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis.
Lancet. 2010; 376: 1916-1922
3
The Incremental Decrease in End Points Through Aggressive Lipid Lowering trial (n =
8,863) confirmed these findings.
- Athyros V.G.
- Giouleme O.
- Ganotakis E.S.
- Elisaf M.
- Tziomalos K.
- Vassiliadis T.
- Liberopoulos E.N.
- Elisaf M.
- Tziomalos K.
- Vassiliadis T.
- Liberopoulos E.N.
for the Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes
(ATTEMPT) Collaborative Group
Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT Study.
Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT Study.
Arch Med Sci. 2011; 7: 796-805
4
Post hoc analyses of the previously mentioned studies
- Tikkanen M.J.
- Fayyad R.
- Faergeman O.
- Olsson A.G.
- Wun C.C.
- Laskey R.
- Kastelein J.J.
- Holme I.
- Pedersen T.R.
IDEAL Investigators
Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels.
Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels.
Int J Cardiol. 2013; 168: 3846-3852
2
,
- Athyros V.G.
- Tziomalos K.
- Gossios T.D.
- Griva T.
- Anagnostis P.
- Kargiotis K.
- Pagourelias E.D.
- Theocharidou E.
- Karagiannis A.
- Mikhailidis D.P.
GREACE Study Collaborative Group
Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis.
Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis.
Lancet. 2010; 376: 1916-1922
3
,
- Athyros V.G.
- Giouleme O.
- Ganotakis E.S.
- Elisaf M.
- Tziomalos K.
- Vassiliadis T.
- Liberopoulos E.N.
- Elisaf M.
- Tziomalos K.
- Vassiliadis T.
- Liberopoulos E.N.
for the Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes
(ATTEMPT) Collaborative Group
Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT Study.
Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT Study.
Arch Med Sci. 2011; 7: 796-805
4
reported that high-dose atorvastatin was safe in patients with abnormal liver tests,
probably because of NAFLD, reduced transaminase levels, and also reduced MACE twice
more in these patients compared with those with normal liver biochemistry.
- Tikkanen M.J.
- Fayyad R.
- Faergeman O.
- Olsson A.G.
- Wun C.C.
- Laskey R.
- Kastelein J.J.
- Holme I.
- Pedersen T.R.
IDEAL Investigators
Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels.
Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels.
Int J Cardiol. 2013; 168: 3846-3852
2
,
- Athyros V.G.
- Tziomalos K.
- Gossios T.D.
- Griva T.
- Anagnostis P.
- Kargiotis K.
- Pagourelias E.D.
- Theocharidou E.
- Karagiannis A.
- Mikhailidis D.P.
GREACE Study Collaborative Group
Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis.
Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis.
Lancet. 2010; 376: 1916-1922
3
,
- Athyros V.G.
- Giouleme O.
- Ganotakis E.S.
- Elisaf M.
- Tziomalos K.
- Vassiliadis T.
- Liberopoulos E.N.
- Elisaf M.
- Tziomalos K.
- Vassiliadis T.
- Liberopoulos E.N.
for the Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes
(ATTEMPT) Collaborative Group
Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT Study.
Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT Study.
Arch Med Sci. 2011; 7: 796-805
4
Recently, we reported that monotherapy with rosuvastatin 10 mg/day ameliorated liver
histology in biopsy-proved nonalcoholic steatohepatitis, an advanced/severe form of
NAFLD, and resolved metabolic syndrome within 12 months.
- Tikkanen M.J.
- Fayyad R.
- Faergeman O.
- Olsson A.G.
- Wun C.C.
- Laskey R.
- Kastelein J.J.
- Holme I.
- Pedersen T.R.
IDEAL Investigators
Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels.
Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels.
Int J Cardiol. 2013; 168: 3846-3852
5
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Impact of nonalcoholic fatty liver disease on myocardial perfusion in nondiabetic patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.Am J Cardiol. 2015; 116: 1810-1814
- Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis.Lancet. 2010; 376: 1916-1922
- Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT Study.Arch Med Sci. 2011; 7: 796-805
- Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels.Int J Cardiol. 2013; 168: 3846-3852
- Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome.World J Gastroenterol. 2015; 21: 7860-7868
- Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?.Expert Opin Pharmacother. 2015; 16: 1449-1461
- Efficacy of high-dose rosuvastatin preloading in patients undergoing percutaneous coronary intervention: a meta-analysis of fourteen randomized controlled trials.Lipids Health Dis. 2015; 14: 97-108
- Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention.Am J Cardiol. 2014; 113: 1753-1764
Article Info
Publication History
Published online: November 08, 2015
Received:
November 2,
2015
Identification
Copyright
© 2016 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Impact of Nonalcoholic Fatty Liver Disease on Myocardial Perfusion in Nondiabetic Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial InfarctionAmerican Journal of CardiologyVol. 116Issue 12
- PreviewLimited data exist on the role of nonalcoholic fatty liver disease (FLD) as a potential independent risk factor in the setting of acute coronary syndromes. The aim of this study was to evaluate the impact of FLD on myocardial perfusion and inhospital major adverse cardiac events (MACE) in the setting of ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI). We examined 186 consecutive nondiabetic patients (mean age 58 ± 11 years and 76% men) who underwent primary PCI for STEMI by ultrasound within 72 hours of admission.
- Full-Text
- Preview